[go: up one dir, main page]

CL2018001488A1 - Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab - Google Patents

Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab

Info

Publication number
CL2018001488A1
CL2018001488A1 CL2018001488A CL2018001488A CL2018001488A1 CL 2018001488 A1 CL2018001488 A1 CL 2018001488A1 CL 2018001488 A CL2018001488 A CL 2018001488A CL 2018001488 A CL2018001488 A CL 2018001488A CL 2018001488 A1 CL2018001488 A1 CL 2018001488A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
aqueous pharmaceutical
antibody
avelumab
avelumab antibody
Prior art date
Application number
CL2018001488A
Other languages
English (en)
Inventor
Gianluca Rinaldi
Rio Alessandra Del
Silvia Fratarcangeli
Senta Voss
Markus Weigandt
Original Assignee
Pfizer
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54838201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018001488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Merck Patent Gmbh filed Critical Pfizer
Publication of CL2018001488A1 publication Critical patent/CL2018001488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN DE ANTICUERPO ANTI-PD-L-1 NOVEDOSA. EN PARTICULAR, LA INVENCIÓN SE REFIERE A UNA FORMULACIÓN FARMACÉUTICA ACUOSA DEL ANTICUERPO ANTI-PD-L1 AVELUMAB.
CL2018001488A 2015-12-07 2018-06-04 Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab CL2018001488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15198233 2015-12-07

Publications (1)

Publication Number Publication Date
CL2018001488A1 true CL2018001488A1 (es) 2018-09-14

Family

ID=54838201

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001488A CL2018001488A1 (es) 2015-12-07 2018-06-04 Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab

Country Status (35)

Country Link
US (2) US11058769B2 (es)
EP (2) EP3747466A1 (es)
JP (1) JP6925337B2 (es)
KR (1) KR102697026B1 (es)
CN (1) CN108367072B (es)
AR (1) AR107014A1 (es)
AU (1) AU2016368099C1 (es)
BR (1) BR112018010211A2 (es)
CA (1) CA3007481C (es)
CL (1) CL2018001488A1 (es)
CO (1) CO2018005525A2 (es)
CY (1) CY1123358T1 (es)
DK (1) DK3386541T3 (es)
EA (1) EA201891339A1 (es)
ES (1) ES2823279T3 (es)
HR (1) HRP20201573T1 (es)
HU (1) HUE050811T2 (es)
IL (1) IL259563B (es)
LT (1) LT3386541T (es)
MX (1) MX389289B (es)
MY (1) MY195681A (es)
NZ (1) NZ743964A (es)
PE (1) PE20181400A1 (es)
PH (1) PH12018500894A1 (es)
PL (1) PL3386541T3 (es)
PT (1) PT3386541T (es)
RS (1) RS61029B1 (es)
SA (1) SA518391743B1 (es)
SG (1) SG11201804758QA (es)
SI (1) SI3386541T1 (es)
SM (1) SMT202000497T1 (es)
TW (1) TWI630917B (es)
UA (1) UA123270C2 (es)
WO (1) WO2017097407A1 (es)
ZA (1) ZA201804534B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851165B2 (en) 2014-10-14 2020-12-01 Novartis Ag Antibody molecules to PD-L1 and methods of treating cancer

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
SG10201913297TA (en) 2015-03-13 2020-02-27 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR102697026B1 (ko) 2015-12-07 2024-08-20 메르크 파텐트 게엠베하 항-pd-l1 항체 아벨루맙을 포함하는 수성 약학 제형
EP3325513A4 (en) 2016-06-13 2018-12-19 I-Mab Anti-pd-l1 antibodies and uses thereof
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
CN110392578B (zh) * 2017-03-06 2024-07-02 默克专利有限公司 水性抗pd-l1抗体制剂
AU2018278327B2 (en) 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof
CN114632150B (zh) 2017-11-02 2023-12-19 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
KR102494021B1 (ko) * 2017-12-22 2023-02-06 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
EP3732197A1 (en) * 2017-12-28 2020-11-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
CA3121288A1 (en) * 2018-11-29 2020-06-04 Harbour Biomed Therapeutics Limited Anti-pd-l1 antibody preparation
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
AU2020304112A1 (en) * 2019-06-25 2022-01-27 Innovent Biologics (Suzhou) Co., Ltd. Formulations containing anti-CD47/PD-L1 bispecific antibody and preparation method therefor and use thereof
TWI844666B (zh) * 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
US12121565B2 (en) 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
CN114846135A (zh) 2019-11-04 2022-08-02 杜克大学 原发性和转移性癌症的治疗
WO2021118321A1 (ko) * 2019-12-13 2021-06-17 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
KR102683876B1 (ko) * 2020-11-11 2024-07-11 가톨릭대학교 산학협력단 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트
IL309662A (en) 2021-07-02 2024-02-01 Univ Yale Compositions and methods for treating cancer
AU2022340804A1 (en) 2021-08-31 2024-03-21 Gennao Bio, Inc. Compositions and methods for treating cancers
AR131718A1 (es) 2023-01-30 2025-04-23 Kymab Ltd Anticuerpos

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI1934236T1 (sl) 2005-09-02 2013-02-28 Glycomimetics, Inc. Heterobifunkcionalni inhibitorji pan-selektina
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
MY188826A (en) * 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
EP2691112B1 (en) * 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
RS61033B1 (sr) * 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
JO3533B1 (ar) * 2012-01-23 2020-07-05 Regeneron Pharma تركيبات ثابته تحتوي على مضادات حيوية مقاومة لـ ang2
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
NZ719036A (en) 2013-09-27 2022-02-25 Genentech Inc Anti-pdl1 antibody formulations
JP6526025B2 (ja) * 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
CN115590953A (zh) * 2014-05-15 2023-01-13 百时美施贵宝公司（Us） 使用抗pd-1抗体和另一种抗癌剂的组合治疗肺癌
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
TW201705954A (zh) 2015-05-14 2017-02-16 輝瑞大藥廠 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑的組合療法
HK1251474A1 (zh) 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗體和pd-1軸結合拮抗劑治療癌症的方法
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
EP3355902B1 (en) 2015-09-30 2022-04-13 Merck Patent GmbH Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
KR102697026B1 (ko) 2015-12-07 2024-08-20 메르크 파텐트 게엠베하 항-pd-l1 항체 아벨루맙을 포함하는 수성 약학 제형
CN110392578B (zh) 2017-03-06 2024-07-02 默克专利有限公司 水性抗pd-l1抗体制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851165B2 (en) 2014-10-14 2020-12-01 Novartis Ag Antibody molecules to PD-L1 and methods of treating cancer

Also Published As

Publication number Publication date
US20180369377A1 (en) 2018-12-27
DK3386541T3 (da) 2020-09-28
TW201725051A (zh) 2017-07-16
AU2016368099B2 (en) 2023-03-09
EP3747466A1 (en) 2020-12-09
LT3386541T (lt) 2020-10-26
SG11201804758QA (en) 2018-07-30
PL3386541T3 (pl) 2021-04-06
SA518391743B1 (ar) 2022-12-01
WO2017097407A1 (en) 2017-06-15
MX389289B (es) 2025-03-20
SI3386541T1 (sl) 2020-11-30
US11058769B2 (en) 2021-07-13
EP3386541B1 (en) 2020-07-08
MX2018006875A (es) 2018-11-09
HRP20201573T1 (hr) 2020-12-11
TWI630917B (zh) 2018-08-01
KR20180085801A (ko) 2018-07-27
PH12018500894A1 (en) 2018-11-05
CN108367072B (zh) 2022-12-27
IL259563B (en) 2021-05-31
IL259563A (en) 2018-07-31
HUE050811T2 (hu) 2021-01-28
AU2016368099A1 (en) 2018-07-19
CY1123358T1 (el) 2021-12-31
EA201891339A1 (ru) 2019-01-31
UA123270C2 (uk) 2021-03-10
KR102697026B1 (ko) 2024-08-20
CO2018005525A2 (es) 2018-08-10
SMT202000497T1 (it) 2021-01-05
ES2823279T3 (es) 2021-05-06
PE20181400A1 (es) 2018-09-07
CA3007481C (en) 2024-01-30
AR107014A1 (es) 2018-03-14
MY195681A (en) 2023-02-03
AU2016368099C1 (en) 2023-10-12
JP2018536676A (ja) 2018-12-13
NZ743964A (en) 2023-03-31
PT3386541T (pt) 2020-10-12
ZA201804534B (en) 2020-11-25
JP6925337B2 (ja) 2021-08-25
BR112018010211A2 (pt) 2019-02-05
CN108367072A (zh) 2018-08-03
HK1257781A1 (zh) 2019-10-25
EP3386541A1 (en) 2018-10-17
RS61029B1 (sr) 2020-12-31
US20210100903A1 (en) 2021-04-08
CA3007481A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
CL2018001488A1 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EP3334824A4 (en) PD-1 ANTIBODY
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
EP3463360A4 (en) AQUEOUS COMPOSITION CONTAINING ATROPINE
BR112016030284A2 (pt) Formulações, seu uso ou produção de detergentes de lavagem de louça e sua produção
EP3383915A4 (en) PD-1 ANTIBODY
MX2017011194A (es) Anticuerpos, usos y métodos.
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2017009827A (es) Formulacion farmaceutica.
GT201600252A (es) Derivados de naftiridinadiona
DK3630698T3 (da) Vandig bindingssammensætning
SMT202200179T1 (it) Composizione acquosa oftalmica.
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EP3498839A4 (en) Anti-pd-1 antibody
EP3305294A4 (en) AQUEOUS MEDICINE
EP3305295A4 (en) AQUEOUS MEDICINE
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента
BR112016027254A2 (pt) Complexo de quitina-glucano, sua preparação e utilizações
TH1601000953A (th) พอลิเพพไทด์ที่เสถียรที่จับเกาะกับคอมพลีเมนต์ c5 ของมนุษย์
TH1501005169A (th) ยาผสมทางเภสัชกรรม